PREOPERATIVE AND POSTOPERATIVE ANTIBIOTIC PROPHYLAXIS IN GYNECOLOGICAL PATIENTS DEPENDING ON INDIVIDUAL RISK FACTORS

Pelvic inflammatory diseases as complications of invasive diagnostics and surgical treatment occur often enough in patients with gynecological disorders. The risk of infectious complications is always individual and depends on many factors. The implementation of a personified approach and optimization of antibacterial prophylaxis can decrease the incidence of inflammatory reactions and reduce the risk of infectious complications.

Objective: to estimate the efficacy and tolerability of combiflox (ornidazole 500 mg + ofloxacin 200 mg) in long-term antibiotic prophylaxis after gynecological and oncological surgeries.

 Materials and methods. We assessed the results of a 7-day oral course of combiflox after intravenous intraoperative antibiotic prophylaxis (ciprofloxacin 500 mg + metronidazole 500 mg) in 73 women that underwent gynecological or oncological surgeries. All patients were monitored for postoperative complications, including any wound inflammation, low-grade hyperthermia, symptoms of postoperative vaginitis, endometritis, limited peritonitis, adnexitis.

Results. We found that 43.8 % of patients were at high risk of developing postoperative inflammatory complications; in most of the cases, it was associated with obesity (body mass index >30 kg/m2). Three out of 32 overweight patients (9.3 %) developed postoperative complications, whereas none of the 41 patients with minimal risk factors had such events. No combiflox-related adverse effects were observed during the study. All patients reported good tolerability and high convenience of the drug.

 Conclusion. The need for long-term antibiotic prophylaxis depends on the type of surgery and individual risks for infectious complications. Low-cost oral therapy with combiflox (ornidazole + ofloxacin) during the postoperative period reduces the risk of infectious complications, especially among patients with a body mass index >30 kg/m2, since they are particularly prone to wound complications.

1. Young H., Knepper B., Vigil C. et al. Sustained reduction in surgical site infection after 12.113.

2. Lake A.G., Mc Pencow A.M., Dick Biascoechea M.A. et al. Surgical site infection aft abdominal hysterectomy. Surg Infect 2013;14(5):460–3. PMID: 23859677. DOI: 10.1089/sur.20er hysterectomy. Am J Obstet Gynecol 2013;209(5):490.e1–9. PMID: 23770467. PMCID: PMC3825793. DOI: 10.1016/j.ajog.2013.06.018.

3. Centers for Disease Control (CDC) Surgical Site Infection (SSI) Event 2016. Available at: http://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf.

4. Berríos-Torres S.I., Umscheid C.A., Bratzler D.W. et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg 2017;152(8):784–91. PMID: 28467526. DOI: 10.1001/jamasurg.2017.0904.

5. Bakkum-Gamez J.N., Dowdy S.C., Borah B.J. et al. Predictors and costs of surgical site infections in patients with endometrial cancer. Gynecol Oncol 2013;130(1):100–66. PMID: 23558053. DOI: 10.1016/j.ygyno.2013.03.022.

6. Aslanov B.I., Zueva L.P., Kolosovskaya E.N. et al. Federal clinical guidelines. Principles of perioperative antibiotic prophylaxis in healthcare institutions. Moscow: Ministry of Health of the Russian Federation, 2014. (In Russ.).

7. Wright J.D., Hassan K., Ananth C.V. et al. Use of guideline-based antibiotic prophylaxis in women undergoing gynecologic surgery. Obstet Gynecol 2013;122(6):1145–53. DOI: 10.1097/AOG.0b013e3182a8a36a.

8. Carri R. Warshak, MD et al. Effect of postcesarean delivery oral cephalexin and metronidazole on surgical site infection among obese women: a randomized clinical trial. JAMA 2017;318(11):1026–34. PMID: 28975304. DOI: 10.1001/jama.2017.10567.

9. Global guidelines for the prevention of surgical site infection. World Health Organization 2016. Available at: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0095752/pdf.

10. Mahdi H., Goodrich S., Lockhart D. et al. Predictors of surgical site infection in women undergoing hysterectomy for benign gynecologic disease: a multicenter analysis using the national surgical quality improvement program data. J Minim invasive Gynecol 2014;21(5):901–9. PMID: 24768957. DOI: 10.1016/j.jmig.2014.04.003.

11. Sivapalasingam S., Steigbigel N.H. Macrolides, clindamcyin and ketolides. In: Principles and Practice of Infectious Diseases. 7th edn. Pennsylvania: Churchill Livingstone Elsevier, 2010. 442 p.

12. Boeckh M., Lode H., Deppermann K.M. et al. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother 1990;34(12):2407–14. PMID: 2088195.

13. Kozachenko A.V., Teslenko I.V., Gubskiy K.A. Comparing the efficacy of ornidazole and metronidazole in patients with purulent inflammation in the abdominal cavity. Meditsina neotlozhnykh sostoyaniy = Emergency Medicine 2012;5(44):56–62. (In Russ.). DOI: 10.17650/1994‑4098‑2018‑14‑1‑86-90